AK 103

Drug Profile

AK 103

Alternative Names: AK-103

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Akeso Biopharma
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cancer

Most Recent Events

  • 20 Mar 2018 Phase-I clinical trials in Cancer in China (unspecified route) (Akeso Biopharma pipeline, March 2018)
  • 13 Sep 2017 AK 103 is available for licensing as of 13 Sep 2017. http://www.akesobio.com/index.php?siteid=2
  • 23 Feb 2017 Preclinical trials in Cancer in China (unspecified route) (Akeso Biopharma pipeline, September 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top